TY - JOUR
T1 - Methods for conducting international Delphi surveys to optimise global participation in core outcome set development
T2 - a case study in gastric cancer informed by a comprehensive literature review
AU - on behalf of the GASTROS International Working Group
AU - Alkhaffaf, Bilal
AU - Blazeby, Jane M.
AU - Metryka, Aleksandra
AU - Glenny, Anne Marie
AU - Adeyeye, Ademola
AU - Costa, Paulo Matos
AU - del Val, Ismael Diez
AU - Gisbertz, Suzanne S.
AU - Guner, Ali
AU - Law, Simon
AU - Lee, Hyuk Joon
AU - Li, Ziyu
AU - Nakada, Koji
AU - Nuñez, Rafael Mauricio Restrepo
AU - Reim, Daniel
AU - Reynolds, John V.
AU - Vorwald, Peter
AU - Zanotti, Daniela
AU - Allum, William
AU - Chaudry, M. Asif
AU - Griffiths, Ewen
AU - Williamson, Paula R.
AU - Bruce, Iain A.
AU - Li, Shuangxi
AU - He, Yu long
AU - Xu, Zekuan
AU - Xue, Yingwei
AU - Liang, Han
AU - Li, Guoxin
AU - Zhao, Enhao
AU - Neumann, Philipp
AU - O’Neill, Linda
AU - Guinan, Emer
AU - Baiocchi, Gian Luca
AU - de Manzoni, Giovanni
AU - Hagens, Eliza R.C.
AU - van Berge Henegouwen, Mark I.
AU - Lages, Patrícia
AU - Onofre, Susana
AU - Cabañas, Gabriel Salcedo
AU - Gonzalez, Maria Posada
AU - Campos, Cristina Marin
AU - Candas, Bahar
AU - Baki, Bahadır Emre
AU - Bodur, Muhammed Selim
AU - Yildirim, Reyyan
AU - Cekic, Arif Burak
AU - Beuscart, Jean Baptiste
AU - Horbach, Sophie
AU - Mecoli, Christopher
N1 - Funding Information:
This study is funded by the National Institute for Health Research (NIHR) Doctoral Research Fellowship Grant (DRF-2015-08-023). JMB is partially funded by the NIHR Bristol Biomedical Research Centre and the MRC ConDUCT-II Hub for Trials Methodology Research. PRW was funded by the MRC North West Hub for Trials Methodology Research (Grant ref: MR/K025635/01).
Funding Information:
The authors would like to highlight the role undertaken by Dr Aleksandra Metryka, Senior Clinical Trials Coordinator, who facilitated the running of this study. In addition, the authors would like to thank the following associations and groups for their support in facilitating recruitment to the GASTROS study Delphi survey: • The International Gastric Cancer Association (www.igca.info) • The Association of Upper Gastro-Intestinal Surgeons of Great Britain and Ireland (www.augis.org) • The Brazilian Gastric Cancer Association (www.abcg.org.br) • The Canadian Gastric Cancer Association (www.gastriccancer.ca) • The Chinese Gastric Cancer Association • The Dutch Upper GI Cancer Group (www.ducg.nl) • The GASTRODATA group (www.gastrodata.org) • Italian Research Group for Gastric Cancer (www.gircg.it) • The Korean Gastric Cancer Association (www.kgca-i.or.kr) • Oesophago-Gastric Surgery Section of the Asociación Española de Cirujanos – Spain (www.aecirujanos.es) • Upper GI International Robotic Association (www.ugira.org) • United Kingdom Oncology Nursing Society (www.ukons.org.uk) • The European Oncology Nursing Society (www.cancernurse.eu) • The Oesophageal Patients Association – UK (www.opa.org.uk) • My Gut Feeling – Canada (www.mygutfeeling.ca) • No Stomach for Cancer – USA (www.nostomachforcancer.org) • Vivere Senza Stomaco - Italy () • Gastro/Oesophageal Support and Help Cancer Group (Bristol) – UK • The Greater Manchester Oesophago-gastric patient support group – UK GASTROS International Working Group Collaborators (to be cited as collaborators in PUBMED) • Shuangxi Li • Yu-long He • Zekuan Xu • Yingwei Xue • Han Liang • Guoxin Li • Enhao Zhao • Philipp Neumann • Linda O’Neill • Emer Guinan • Gian Luca Baiocchi • Giovanni de Manzoni • Eliza R.C. Hagens • Mark I. van Berge Henegouwen • Patrícia Lages • Susana Onofre • Gabriel Salcedo Cabañas • Maria Posada Gonzalez • Cristina Marin Campos • Bahar Candas • Bahadır Emre Baki • Muhammed Selim Bodur • Reyyan Yildirim • Arif Burak Cekic • Jean-Baptiste Beuscart • Sophie Horbach • Christopher Mecoli • Toby O Smith
Funding Information:
This paper presents independent research funded by the National Institute for Health Research (NIHR). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.
Publisher Copyright:
© 2021, The Author(s).
PY - 2021/12
Y1 - 2021/12
N2 - Background: Core outcome sets (COS) should be relevant to key stakeholders and widely applicable and usable. Ideally, they are developed for international use to allow optimal data synthesis from trials. Electronic Delphi surveys are commonly used to facilitate global participation; however, this has limitations. It is common for these surveys to be conducted in a single language potentially excluding those not fluent in that tongue. The aim of this study is to summarise current approaches for optimising international participation in Delphi studies and make recommendations for future practice. Methods: A comprehensive literature review of current approaches to translating Delphi surveys for COS development was undertaken. A standardised methodology adapted from international guidance derived from 12 major sets of translation guidelines in the field of outcome reporting was developed. As a case study, this was applied to a COS project for surgical trials in gastric cancer to translate a Delphi survey into 7 target languages from regions active in gastric cancer research. Results: Three hundred thirty-two abstracts were screened and four studies addressing COS development in rheumatoid and osteoarthritis, vascular malformations and polypharmacy were eligible for inclusion. There was wide variation in methodological approaches to translation, including the number of forward translations, the inclusion of back translation, the employment of cognitive debriefing and how discrepancies and disagreements were handled. Important considerations were identified during the development of the gastric cancer survey including establishing translation groups, timelines, understanding financial implications, strategies to maximise recruitment and regulatory approvals. The methodological approach to translating the Delphi surveys was easily reproducible by local collaborators and resulted in an additional 637 participants to the 315 recruited to complete the source language survey. Ninety-nine per cent of patients and 97% of healthcare professionals from non-English-speaking regions used translated surveys. Conclusion: Consideration of the issues described will improve planning by other COS developers and can be used to widen international participation from both patients and healthcare professionals.
AB - Background: Core outcome sets (COS) should be relevant to key stakeholders and widely applicable and usable. Ideally, they are developed for international use to allow optimal data synthesis from trials. Electronic Delphi surveys are commonly used to facilitate global participation; however, this has limitations. It is common for these surveys to be conducted in a single language potentially excluding those not fluent in that tongue. The aim of this study is to summarise current approaches for optimising international participation in Delphi studies and make recommendations for future practice. Methods: A comprehensive literature review of current approaches to translating Delphi surveys for COS development was undertaken. A standardised methodology adapted from international guidance derived from 12 major sets of translation guidelines in the field of outcome reporting was developed. As a case study, this was applied to a COS project for surgical trials in gastric cancer to translate a Delphi survey into 7 target languages from regions active in gastric cancer research. Results: Three hundred thirty-two abstracts were screened and four studies addressing COS development in rheumatoid and osteoarthritis, vascular malformations and polypharmacy were eligible for inclusion. There was wide variation in methodological approaches to translation, including the number of forward translations, the inclusion of back translation, the employment of cognitive debriefing and how discrepancies and disagreements were handled. Important considerations were identified during the development of the gastric cancer survey including establishing translation groups, timelines, understanding financial implications, strategies to maximise recruitment and regulatory approvals. The methodological approach to translating the Delphi surveys was easily reproducible by local collaborators and resulted in an additional 637 participants to the 315 recruited to complete the source language survey. Ninety-nine per cent of patients and 97% of healthcare professionals from non-English-speaking regions used translated surveys. Conclusion: Consideration of the issues described will improve planning by other COS developers and can be used to widen international participation from both patients and healthcare professionals.
UR - http://www.scopus.com/inward/record.url?scp=85109014591&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85109014591&partnerID=8YFLogxK
U2 - 10.1186/s13063-021-05338-x
DO - 10.1186/s13063-021-05338-x
M3 - Article
C2 - 34154641
AN - SCOPUS:85109014591
SN - 1745-6215
VL - 22
JO - Trials
JF - Trials
IS - 1
M1 - 410
ER -